Compare TMCI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMCI | CRDF |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 130.7M |
| IPO Year | 2021 | 2012 |
| Metric | TMCI | CRDF |
|---|---|---|
| Price | $1.76 | $1.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $4.77 | ★ $9.63 |
| AVG Volume (30 Days) | ★ 860.9K | 717.9K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $212,690,000.00 | $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.59 | ★ 49.61 |
| 52 Week Low | $1.17 | $1.48 |
| 52 Week High | $7.78 | $4.56 |
| Indicator | TMCI | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 44.32 |
| Support Level | $1.24 | $1.51 |
| Resistance Level | $2.25 | $1.68 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 32.50 | 24.07 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.